HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference [Yahoo! Finance]
HUTCHMED (China) Limited - American Depositary Shares (HCM)
NASDAQ:AMEX Investor Relations:
chi-med.com/investors/information-for-shareholders
Company Research
Source: Yahoo! Finance
the company reported 2025 profitability (net profit $457M, including a $416M one-time divestment gain) with oncology revenue of $286M. 2026 revenue guidance of $330–$450 million reflects expected China growth for FRUZAQLA and potential new partnerships, supported by Takeda launching FRUZAQLA in 38 countries and stronger China sales such as ELUNATE (+33% H2 vs H1). Savolitinib SAFFRON readout targeted in the second half of this year — a positive result could lead to an FDA filing and global commercialization via AstraZeneca, with SANOVO enrollment complete and other savolitinib regulatory filings progressing in China. Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at the 30th Deutsche Bank deposit receipts virtual investor conference. 2025 f
Show less
Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCM alerts
High impacting HUTCHMED (China) Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
HCM
News
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaGlobeNewswire
- HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026GlobeNewswire
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in ChinaGlobeNewswire
- HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]Yahoo! Finance
- HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
HCM
Sec Filings
- 4/29/26 - Form 6-K
- 4/9/26 - Form 6-K
- 4/9/26 - Form 6-K
- HCM's page on the SEC website